Hum Mol Genet 2008, 17: 1427–1435.PubMedCrossRef LY3039478 39. Haruta M, Arai Y, Sugawara W, Watanabe N, Honda S, Ohshima J, Soejima H, Nakadate H, Okita H, Hata J, et al.: Duplication of paternal IGF2 or loss of maternal IGF2 imprinting occurs in half of Wilms tumors with various

structural WT1 abnormalities. Genes Chromosomes Cancer 2008, 47: 712–727.PubMedCrossRef 40. Yusenko MV, Kuiper RP, Boethe T, Ljungberg B, van Kessel AG, Kovacs G: High-resolution DNA copy number and gene expression analyses distinguish chromophobe renal cell carcinomas and renal oncocytomas. BMC Cancer 2009, 9: 152.PubMedCrossRef 41. Cutcliffe C, Kersey D, Huang CC, Zeng Y, Walterhouse D, Perlman EJ: Clear cell sarcoma of the kidney: up-regulation of neural markers with activation of the sonic hedgehog and Akt pathways. Clin Cancer Res 2005, 11: 7986–7994.PubMedCrossRef 42. Lenburg ME, Liou LS, Gerry NP, Frampton GM, Cohen HT, Christman MF: Previously unidentified changes in renal cell carcinoma gene expression identified by parametric analysis of microarray Vadimezan cell line data. BMC Cancer 2003, 3: 31.PubMedCrossRef 43. Gumz ML, Zou H, Kreinest PA, Childs AC, Belmonte LS, LeGrand SN, Wu KJ, Luxon BA, Sinha M, Parker AS, et al.: Secreted frizzled-related protein 1 loss contributes to tumor phenotype

of clear cell renal cell carcinoma. Clin Cancer Res 2007, 13: 4740–4749.PubMedCrossRef 44. Beroukhim R, Brunet JP, Di Napoli A, Mertz KD, Seeley A, Pires MM, Linhart D, Worrell RA, Moch H, Rubin MA, et

al.: Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res 2009, 69: 4674–4681.PubMedCrossRef Competing interests The authors declare that they have no competing interests. Authors’ contributions KB performed the database interrogation why and the SOSTDC1 LOH analysis and sequencing. KC carried out the sample staining and manuscript preparation. GH oversaw the SOSTDC1 LOH analysis and sequencing. AG assisted with the Wilms tumor tissue procurement. MW provided technical advice and interpretations for the immunohistochemistry results. JT aided in the SOSTDC1 LOH analysis and sequencing. FT assisted with the experimental design and interpretation. ST oversaw experiment planning, interpretation, and manuscript preparation. The final manuscript was read and approved by all authors.”
“Background Hepatoma is the sixth most common cancer worldwide. Its incidence increased rapidly and becomes the leading cause of cancer-related deaths in the world[1]. To date, chemotherapy has been the most frequently used Selleck PF-4708671 treatment for liver cancer and other cancers. However, The toxicity of these chemotherapy medicines to normal tissues and normal cells has been one of the major obstacles to successful cancer chemotherapy. Obviously, there is an urgent need to identify new therapeutic agents for the treatment of hepatoma.